Zydus Lifesciences informs about outcome of board meeting

07 Nov 2023 Evaluate
Zydus Lifesciences has informed that Board of Directors at their meeting held today November 7, 2023, based on the recommendations of Audit Committee, approved the unaudited financial results for the quarter / half year ended on September 30, 2023. In this regard, it enclosed the following; the unaudited financial results (standalone and consolidated) for the quarter / half year ended on September 30, 2023, reviewed by the Audit Committee and taken on record by the Board of Directors pursuant to regulation 33 of the Listing Regulations; the limited review reports of Deloitte Haskins & Sells LLP, Chartered Accountants and the Statutory Auditors of the Company (Deloitte) certifying the limited review of the unaudited financial results (standalone and consolidated) of the Company for the quarter / half year ended on September 30, 2023 pursuant to regulation 33 of the Listing Regulations; The Trading Window under SEBI (Prohibition of Insider Trading) Regulations, 2015 shall remain closed for trading till Thursday, November 9, 2023 and shall reopen on and from Friday, November 10, 2023 for the Directors and Designated Persons; The Board meeting commenced at 10.50 am and concluded at 11.55 am.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

876.10 3.15 (0.36%)
21-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.55
Dr. Reddys Lab 1155.50
Cipla 1369.55
Zydus Lifesciences 876.10
Lupin 2139.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×